Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium

Current Eye Research

Volumn 33, Issue 1, 2008, Pages 23-28

  Bahar, Irit ^a,b   Kaiserman, Igor ^a   McAllum, Penny ^a   Rootman, David ^a   Slomovic, Allan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Bevacizumab; Pterygium; Recurrent

Indexed keywords

BEVACIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CORNEA VASCULARIZATION; DRUG TOLERABILITY; HUMAN; IMAGE ANALYSIS; MEDICAL RECORD REVIEW; PHOTOGRAPHY; PRIORITY JOURNAL; PTERYGIUM; RECURRENT DISEASE; RETROSPECTIVE STUDY; STUDENT T TEST; TONOMETRY; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CONJUNCTIVA; CORNEAL NEOVASCULARIZATION; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MIDDLE AGED; PTERYGIUM; RECURRENCE; RETROSPECTIVE STUDIES; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 38549121685     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680701799101     Document Type: Article

References (30)

1. Hill JC, Maske R. Pathogenesis of pterygium. Eye. 1989;3:218-226.
2. Cameron ME. Histology of pterygium: An electron microscopic study. Br J Ophthalmol. 1983;67:604-608.
3. Cilova-Atanasova B. On the pathogenesis of pterygium. Folia Med (Plovdiv). 1971;13:67-74.
4. Tan DT, Chee SP, Dear KB, et al. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol. 1997;115:1235-1240.
5. Coroneo MT, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol. 1999;10:282-288.
6. Pinkerton OD, Hokama Y, Shigemura LA. Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol. 1984;98(2):225-228.
7. Solomon AS. Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol. 1985;99:216-217.
8. Tsironi S, Ioachim E, Machera M, et al. Immunohistochemical HLA-DR antigen expression with lymphocyte subsets and proliferative activity in pterygium. In Vivo. 2002;16:299-306.
9. Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem. 1996;98:195-201.
10. Kria L, Ohira A, Amemiya T. Growth factors in cultured pterygium fibroblasts: Immunohistochemical and ELISA analysis. Graefes Arch Clin Exp Ophthalmol. 1998;236:702-708.
11. Powers MR, Qu Z, O'Brien B, et al. Immunolocalization of bFGF in pterygia: Association with mast cells. Cornea. 1997;16:545-549.
12. Lee DH, Cho HJ, Kim JT, et al. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea. 2001;20:738-742.
13. Lee JK, Song YS, Ha HS, et al. Endothelial progenitor cells in pterygium pathogenesis. Eye. 2007;21:1186-1193.
14. Jin J, Guan M, Sima J, et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea. 2003;22:473-477.
15. Hurwitz H, Fehrenbacher L, Novotny W, et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
16. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005;112:1048-1053.
17. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047.
18. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthal Surg Lasers Imaging. 2005;36:331-335.
19. Nguyen QD, Shah S, Tatlipinar S, et al. Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol. 2005;89:1368-1370.
20. Di Girolamo N, Coroneo MT, Wakefield D. Active matrilysin (MMP-7) in human pterygia: Potential role in angiogenesis. Invest Ophthalmol Vis Sci. 2001;42:1963-1968.
21. Coroneo MT, Di Girolamo N, Wakefield D. The pathogenesis of pterygia. Curr Opin Ophthalmol. 1999;10:282-288.
22. Jimenez B, Volpert OV. Mechanistic insights on the inhibition of tumor angiogenesis. J Mol Med. 2001;78:663-672.
23. Miller JW. Vascular endothelial growth factor and ocular neovascularization. Am J Pathol. 1997;151:13-23.
24. Manzano R, Peyman G, Khan P, Carvounis P, Kivilcim M, Ren M, Lake J, Chevez-Barrios P. Inhibition of experimental corneal neovascularization by Bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804-807.
25. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245:1577-1579.
26. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. (accepted for publication).
27. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
28. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
29. Avery R L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26:352-354.
30. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275-278.